T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system

Minori Tamai1, Takeshi Inukai1, Satoru Kojika2, Masako Abe1, Keiko Kagami1, Daisuke Hara1a, Tamao Shinohara3, Atsushi Watanabe1, Hiroko Oshiro1, Koshi Akahane1, Kumiko Goi1, Eiji Sugihara2, Shinichiro Nakada3 & Kanji Sugita1

In many cancers, somatic mutations confer tumorigenesis and drug-resistance. The recently established clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system is a potentially elegant approach to functionally evaluate mutations in cancers. To reproduce mutations by homologous recombination (HR), the HR pathway must be functional, but DNA damage repair is frequently impaired in cancers. Imatinib is a tyrosine kinase inhibitor for BCR-ABL1 in Philadelphia chromosome-positive (Ph+) leukemia, and development of resistance due to kinase domain mutation is an important issue. We attempted to introduce the T315I gatekeeper mutation into three Ph+ myeloid leukemia cell lines with a seemingly functional HR pathway due to resistance to the inhibitor for poly (ADP) ribose polymerase1. Imatinib-resistant sublines were efficiently developed by the CRISPR/Cas9 system after short-term selection with imatinib; resulting sublines acquired the T315I mutation after HR. Thus, the usefulness of CRISPR/Cas9 system for functional analysis of somatic mutations in cancers was demonstrated.

Imatinib is a tyrosine kinase inhibitor (TKI) against BCR-ABL1 fusion tyrosine kinase derived from Philadelphia chromosome in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)1,2. Imatinib can achieve durable cytogenetic and molecular remissions not only in CML patient3 but also in patients with Ph+ ALL in combination with conventional chemotherapy4,5. Despite the remarkable success of imatinib, resistance has been identified due to point mutations in the BCR-ABL1 kinase domain2,6,7. Among these mutations, the T315I gatekeeper mutation confers resistance to both imatinib6,8 and second-generation TKIs such as nilotinib and dasatinib5. Finally, ponatinib was developed as a potent TKI that can inhibit all critical kinase domain mutations including T315I10.

To investigate the biological significance of T315I mutation and to develop the therapeutic strategy overcoming TKI-resistance, a line of cellular models of T315I-positive leukemia was established. The most common system was murine IL-3-dependent BaF3 cells expressing BCR-ABL1 or its mutant cDNAs that were transduced with retrovirus vector8,11-13. BCR-ABL1 and its mutants induced spontaneous cell growth of BaF3 in the absence of IL-3. The other commonly used system was imatinib-resistant sublines of human Ph+ leukemia cell lines. A couple of imatinib-resistant sublines with T315I mutation were established after long-term culture of imatinib-sensitive Ph+ leukemia cell lines in the presence of increasing concentrations of imatinib14-17. However, it has also been reported that long-term culture with increasing concentrations of imatinib induced imatinib resistance due to amplification of the BCR-ABL1 fusion gene and overexpression of P-glycoprotein (P-gp)18,19. This suggests that imatinib-resistant sublines with T315I (established after long-term selection with imatinib)

1Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan. 2Innovation Medical Research Institute, Research and Development Center for Precision Medicine, University of Tsukuba, Ibaraki, Japan. 3Department of Bioregulation and Cellular Response, Graduate School of Medicine, Osaka University, Osaka, Japan. Correspondence and requests for materials should be addressed to T.I. (email: tinukai@yamanashi.ac.jp)
may acquire additional mechanisms for imatinib resistance. Thus, to directly test the effect of the T315I mutation, establishing a new system that enables the T315I mutation to be introduced into imatinib-sensitive Ph+ leukemia cell lines without long-term imatinib selection is desirable. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system consists of a Cas9 endonuclease and a single-guide RNA (sgRNA) that allows sequence-specific gene editing in mammalian cells \(^{20-22}\). CRISPR/Cas9 effectively introduces target double-stranded breaks (DSBs) by recognizing a NGG 3-base-pair protospacer adjacent motif (PAM) and causing hybridization between the 20-nucleotide stretch of the sgRNA and the DNA target site, which triggers Cas9 to cleave both DNA strands. DSBs activate two intrinsic repair mechanisms: non-homologous end-joining (NHEJ) and homologous recombination (HR). NHEJ (the predominant pathway for repair of DSBs) can introduce unpredictable insertions and deletions (indels) resulting in knockout alleles through the introduction of frame-shift mutations. HR is achieved in the presence of a single-stranded oligodeoxynucleotides (ssODN) template homologous to the sequences flanking the cleavage site. HR using the CRISPR/Cas9 system could be useful for introducing the T315I mutation into human Ph+ leukemia cell lines; however, to our knowledge, no reports have described success in purely introducing the point mutation of endogenous gene into human leukemia cells by HR using the CRISPR/Cas9 system.

To introduce HR-mediated gene editing with the CRISPR/Cas9 system in leukemia cells, the intrinsic HR pathway of leukemia cells must be functionally active. Most cancer cells demonstrate increased genomic instability due to impairment in repair pathways for DNA damage \(^{22}\). This seems to be true in Ph+ leukemia cells \(^{24}\). Although inactivating mutations in the HR pathway has been rare in leukemia \(^{24}\), BCR-ABL1 reportedly represses genes involved in the HR pathway such as BRCA1 and RAD51 \(^{24-28}\). These observations suggest that DSBs by the CRISPR/Cas9 system might fail to induce HR-mediated gene editing in Ph+ leukemia cells. Poly (ADP) ribose polymerase 1 (PARP1) repairs DNA single-stranded breaks (SSBs). Inhibitors for PARP1 have recently been identified and are promising agents for cancer treatment \(^{23,24,29-32}\). PARP1 inhibitors generate DSBs during the replication process by trapping the inactivated PARP1 onto the SSB and/or disrupting the DNA repairment. Subsequently, PARP1 inhibitors induce apoptosis of cancer cells that have deficiency in key components of the HR pathway, which utilizes the sister chromatid as a template for a correct repairment of the DNA sequence. In contrast, cancer cells with intact HR pathways repair DSBs and show resistance to PARP1 inhibitors. Thus, sensitivities of cancer cells to PARP1 inhibitors might be useful to evaluate their status of the HR pathway.

In the present study, using the CRISPR/Cas9 system and ssODN, we attempted to introduce the T315I mutation into three Ph+ myeloid leukemia cell lines that showed resistance to olaparib (a PARP1 inhibitor). After short-term imatinib selection, we obtained imatinib-resistant sublines and confirmed that imatinib-resistant sublines successfully acquired T315I mutation of BCR-ABL1 as a result of HR-mediated gene editing.

### Results

#### Ph+ myeloid leukemia cell lines showed resistance to PARP1 inhibitor.

To introduce a T315I mutation in Ph+ leukemia cell lines by HR-mediated gene editing with the CRISPR/Cas9 system, the endogenous HR pathway must be functionally active. However, previous reports demonstrated that BCR-ABL1 represses genes involved in the HR pathway such as BRCA1 and RAD51 \(^{24-28}\). To select Ph+ leukemia cell lines with functional HR pathway, we evaluated the sensitivity to olaparib (one of PARP1 inhibitors) \(^{32}\). We determined the IC\(_{50}\) values of olaparib in 20 Ph+ (16 lymphoid and 4 myeloid) leukemia cell lines in comparison with 77 Ph−negative (Ph−) B-cell precursor ALL (B-CP-ALL) cell lines using the alamarBlue cell viability assay (Table 1 and Fig. 1a). Distributions of mean IC\(_{50}\) values of three independent assays were similar between 16 Ph+ and 77 Ph− lymphoid leukemia cell lines (Fig. 1b). Median IC\(_{50}\) was 5.8μM and 4.7μM in Ph+ and Ph− lymphoid leukemia cell lines, respectively. Of note, all Ph+ myeloid leukemia cell lines were highly resistant to olaparib (Fig. 1a,b), suggesting that the HR pathway is functionally active in these Ph+ myeloid leukemia cell lines.

#### Introduction of T315I mutation using the CRISPR/Cas9 system.

To introduce T315I mutation by HR-mediated gene editing with the CRISPR/Cas9 system, we prepared two CRISPR guide sequences close to the target site (Fig. 2a). Forward sgRNA binds downstream of the target site in the coding strand direction, while reverse sgRNA binds upstream of the target site in the non-coding strand direction. Off-target hit scores of forward and reverse sgRNAs were 70 and 55, respectively, using a CRISPR design tool (CRISPR DESIGN, http://crispr.mit.edu), suggesting a high on-target activity. Two Cas9 cleavage sites were separated from the target site by 12 and 10 bases in forward and reverse sgRNAs, respectively. As a template for HR, two complementary ssODNs of 102 bases in length were designed (Fig. 2a); one was sense direction and the other was anti-sense direction. Both ssODNs contain a single nucleotide transition of ACT to ATT at codon 351 resulting in T315I. To avoid re-cutting of repaired target loci, three silent point mutations were additionally introduced (Fig. 2a). One of three silent point mutations was designed to induce a new EcoRI site (gagaattc).

#### Introduction of T315I mutation in K562.

Among four Ph+ myeloid cell lines, we first used K562, which is the most commonly used Ph+ myeloid cell line for the study of TKI sensitivity. To increase HR efficiency, we treated K562 cells with SCR7 (an inhibitor for a DNA ligase IV that is a key enzyme for NHEJ) \(^{33,34}\) before and during treatment of the CRISPR/Cas9. We electroporated recombinant Cas9 protein in combination with either forward or reverse sgRNAs and either sense or anti-sense ssODNs. Forty-eight hours after transfection (Fig. 2b), cells were plated into 10 wells of 24-well plate and cultured for 5 more days in the absence of imatinib. Subsequently, the cells were cultured in the presence of 1μM of imatinib. When the imatinib-resistant cells were selectively expanded, the cells were transferred to culture flask and expanded in the absence of imatinib for further experiments. Imatinib-resistant sublines were obtained in all four combinations of sgRNAs and ssODNs up to day 26 of the imatinib selection (Fig. 2c), while no imatinib-resistant cells were expanded in parental cells during imatinib selection for 30 days (data not shown). Among the four combinations, the combination of...
reverse sgRNA and anti-sense ssODN revealed significantly higher efficiency than the three other combinations (p < 0.001 in Kaplan-Meier test). To verify whether imatinib-resistant sublines acquired the T315I mutation as a result of HR-mediated gene editing, we extracted genomic DNA, amplified the 427 bp fragment of the ABL1 gene containing exon 6 by PCR using primers in introns 5 and 6, and subsequently tested EcoRI digestion of each PCR product (Fig. 2d). PCR products of all seven sublines tested were partially digested with EcoRI, whereas that of parental cells was not. Direct sequencing (Fig. 2e) confirmed mixture of T315I and additional silence point mutations with wild-type sequence in each imatinib-resistant subline, indicating that imatinib-resistant sublines acquired the T315I mutation as a result of HR-mediated gene editing with the CRISPR/Cas9 system.

**Table 1.** Characterization and olaparib sensitivity of Ph+ leukemia cell lines.

| Cell line  | Type            | BCR-ABL1 | IC50 of olaparib (μM) |
|------------|-----------------|----------|-----------------------|
|            |                 |          | Median | Range |
| **Myeloid**|                 |          |        |       |
| KS62       | CML-BC          | t201     | >20    | >20   |
| TCCS       | CML-BC          | t201     | >20    | >20   |
| KOPM28     | CML-BC          | t201     | >20    | >20   |
| KOPM30     | Ph+ AML         | p190     | >20    | >20   |
| **Lymphoid**|                |          |        |       |
| KOPN30bs   | Ph+ ALL         | p190     | 1.7    | 1.2–2.1 |
| KOPN55b    | CML-BC          | t201     | >20    | >20   |
| KOPN56     | Ph+ ALL         | t201     | 1.6    | 3.4–>20 |
| KOPN57bs   | Ph+ ALL         | p190     | 2.6    | 1.1–3  |
| KOPN66bs   | Ph+ ALL         | p190     | 3      | 2.3–3.5 |
| KOPN72bs   | Ph+ ALL         | p190     | 6.4    | 3.4–9.4 |
| KOPN83bs   | Ph+ ALL         | p190     | 5.2    | 4.4–>20 |
| YAMN73     | Ph+ ALL         | p203     | >20    | >20   |
| YAMN91     | Ph+ ALL         | p190     | >20    | >20   |
| Kasum8     | Ph+ ALL         | p190     | >20    | >20   |
| Nalm1      | CML-BC          | t210     | 1.3    | 0.3–1.5 |
| Nalm27     | Ph+ ALL         | t210     | 4.1    | 4–4.4  |
| KCB1       | Ph+ ALL         | p190     | >20    | >20   |
| TCCY       | Ph+ ALL         | t210     | >20    | >20   |
| SU-Ph2     | Ph+ ALL         | p190     | 1.3    | 0.57–2.6 |
| SK9        | Ph+ ALL         | p190     | 1.3    | 1–1.6  |

**Figure 1.** Sensitivity of Ph+ leukemia cell lines to PARP1 inhibitor. (a) Dose-response curve of olaparib sensitivity in Ph+ leukemia cell lines. The vertical axis indicates the percentage (%) viability in the alamarBlue cell viability assay and the horizontal axis indicates log concentration of olaparib (μM). Left and right panels indicate the sensitivities of Ph+ lymphoid and Ph+ myeloid cell lines, respectively. (b) Olaparib sensitivity in 16 Ph+ lymphoid, 4 Ph+ myeloid, and 77 Ph-negative lymphoid leukemia cell lines. The vertical axis indicates the IC50 value of olaparib. The IC50 value of cell lines in each group is also represented by a boxplot.

Significance of SCR7 treatment in the HR efficiency. Next, we verified the significance of SCR7 treatment in HR efficiency. We electroporated recombinant Cas9 protein in combination with reverse sgRNA
and anti-sense ssODN (which showed the highest HR efficiency in the above analyses) into K562 cells with or without SCR7 treatment. We also electroporated recombinant Cas9 protein in combination with reverse sgRNA and carrier ssODN (which is not template for HR but enables to induce similar transfection efficiency) into K562 cells treated with SCR7. Electroporated cells were cultured in the same way as shown in Fig. 2b. Imatinib-resistant sublines were obtained relatively faster in the cells treated with SCR7 (Fig. 2f) (up to day 17 of imatinib selection) than the untreated cells (up to day 22), although no statistically significant difference was observed between the two groups (p = 0.198 in Kaplan-Meier test). Of note, no imatinib-resistant subline was obtained without specific template ssODN during imatinib selection over 30 days.

**Induction of T315I mutation in TCCS and KOPM28 using the CRISPR/Cas9 system.** Next, we introduced the T315I mutation into two other Ph+ myeloid cell lines (TCCS and KOPM28) resistant to olaparib (Fig. 1). We electroporated recombinant Cas9 protein in combination with reverse sgRNA and anti-sense ssODN into two cell lines treated with SCF7. The electroporated cells were cultured in the same way as shown in Fig. 2b. Imatinib-resistant sublines were efficiently obtained (Fig. 3a) in both TCCS (up to day 9 of imatinib selection) and KOPM28 (up to day 13). Parental cells of TCCS and KOPM28 were completely killed during 14 days culture in the presence of 1 μM imatinib (data not shown). PCR products of genomic DNA from 12 imatinib-resistant sublines of TCCS and KOPM28 were partially digested with EcoRI, unlike those from parental cells (Fig. 3b). Direct sequence of the PCR products from three representative sublines of TCCS (Fig. 3c) and KOPM28 (Fig. 3d)
revealed T315I and additional silence point mutations as the main signal, indicating that imatinib-resistant sublines acquired the T315I mutation as a result of HR-mediated gene editing.

No sign of additional mechanisms for imatinib-resistance in T315I-acquired sublines. Upregulation of BCR-ABL1 protein due to amplification of the BCR-ABL1 fusion gene [29] and overexpression of P-gp [30] were observed in the imatinib-resistant sublines established after long-term culture of imatinib-sensitive Ph+ leukemia cell lines in the presence of increasing concentrations of imatinib. Thus, T315I sublines of three cell lines may acquire these additional mechanisms for imatinib-resistance during imatinib selection. To rule out these possibilities, we evaluated BCR-ABL1 protein expression level in parental cells and imatinib-resistant sublines of three cell lines by Western blotting (Fig. 4a). BCR-ABL1 protein expression levels were similar in both parental cells and imatinib-resistant sublines (T315I #1 and #2) of three cell lines. Thus, amplification of the BCR-ABL1 fusion gene is unlikely to be associated with imatinib-resistant phenotype.

Next, we analyzed cell surface expression level of P-gp by flow cytometry (Fig. 4b). P-gp expression in three parental cell lines showed different patterns: K562 showed two peaks of major negative and minor positive populations, while TCCS and KOPM28 showed single negative and single positive population, respectively. The expression patterns of P-gp in imatinib-resistant sublines of three cell lines (T315I #1 and #2) were identical to their parental cells thus demonstrating that upregulation of P-gp was not associated with the imatinib-resistant phenotype.

Acquisition of T315I mutation in ABL1 transcripts of imatinib-resistant sublines. In western blotting analysis (Fig. 4a), ABL1 protein was detectable in K562 but not in TCCS and KOPM28. ABL1 gene consists of 11 exons with alternative splicing exons of 1a and 1b [31]. In the p210 type of BCR-ABL1 fusion, exons 2–11 of the ABL1 gene are fused to exons 1–13 of the BCR gene [32]. Thus, exons 1a and 1b of the ABL1 gene are specific for ABL1 gene, while exons 2–11 of the ABL1 gene are present in both ABL1 and BCR-ABL1 transcripts. Consistent with protein expression, ABL1-specific RT-PCR products with primers in exons 1a or 1b and 2 of the ABL1 gene were detectable in K562 but not in TCCS and KOPM28 (Fig. 5a). In contrast, RT-PCR products with primers in exons 6 and 7 were detectable in three cell lines. These observations demonstrated that K562 has...
ABL1 and BCR-ABL1 alleles whereas TCCS and KOPM28 have only the BCR-ABL1 allele. Thus, ABL1 allele is another target of the CRISPR/Cas9 system in K562. To distinctly evaluate the ABL1 and BCR-ABL1 alleles in K562 cells, we performed RT-PCR analyses using two sets of primers (Fig. 5b). Primers in exons 1a/b and 6 of...
the ABL1 gene were specific for ABL1 transcripts, while those in exon 13 of the BCR gene and exon 6 of the ABL1 gene were specific for BCR-ABL1 transcripts. We directly sequenced the RT-PCR products of parental cells as well as five imatinib-resistant sublines of K562 with the reverse primer (Fig. 5b). BCR-ABL1 transcripts showed two patterns; sublines #1 and #2 revealed mixed pattern of native and HR sequences, while sublines #11, #12, and #13 predominantly showed HR sequence. Taken together, all five sublines had T315I mutation of the BCR-ABL1 transcripts as a result of HR-mediated gene editing. ABL1 transcripts in imatinib-resistant sublines showed diverse patterns (Fig. 5c); subline #1 revealed mixed pattern of native and HR sequences, subline #2 mainly revealed native sequence, subline #11 mainly revealed HR sequence, subline #12 revealed mixed pattern of native sequence and one base deletion due to NHEJ, and subline #13 revealed mixed pattern of one base insertion due to NHEJ and HR sequence. Taken together, T315I mutation due to HR-mediated gene editing was detectable in three of five sublines.

**Imatinib-resistance in T315I-acquired sublines.** To precisely confirm the effect of the T315I mutation, we first analyzed the phosphorylation status of CRKL (one of critical downstream key enzymes of BCR-ABL1)36,37 using flow cytometry (Fig. 6a). In the parental cells of three cell lines, CRKL was dephosphorylated by imatinib treatment. In contrast, in the T315I-acquired subline of three cell lines, CRKL was constitutively phosphorylated, even after imatinib treatment. Next, we analyzed the induction of cell cycle arrest (Fig. 6b) and apoptotic cell death (Fig. 6c) by imatinib using flow cytometry. Imatinib treatment of parental cells induced accumulation into the G0/G1 phase in K562 and KOPM28. Furthermore, in parental cells of TCCS, over half of the treated cells accumulated into the sub-G0/G1 phase. In contrast, in T315I-acquired sublines of three cell lines, cell cycle arrest was not induced by imatinib treatment. Furthermore, imatinib treatment induced apoptotic cell death in parental cells, but not in the T315I-acquired sublines of three cell lines. We finally determined dose-response curves of imatinib using the alamarBlue cell viability assay (Fig. 6d). T315I-acquired sublines of three cell lines showed a marked resistance to imatinib (up to 10 μM).

**Drug sensitivities of T315I-acquired sublines.** We evaluated the sensitivities to second-generation TKIs using the alamarBlue cell viability assays. T315I-acquired sublines of three cell lines showed marked resistance to nilotinib (Fig. 7a) and dasatinib (Fig. 7b) — up to 1 μM and 100 nM, respectively. Next, we evaluated the sensitivity to ponatinib (Fig. 7c). Parental cells and T315I-acquired sublines of K562 showed similar dose-response curves, and their IC50 values were approximately 100 nM, which was lower than mean peak concentration (137 nM) of orally administrated ponatinib (45 mg daily) at steady state39. Parental cells of TCCS and KOPM28 were highly sensitive to ponatinib and their IC50 values were less than 0.1 nM. T315I sublines of TCCS and KOPM28 were significantly more resistant to ponatinib than their parental cells; their IC50 values were approximately 0.2 nM and 20 nM, respectively. We also analyzed the sensitivities to chemotherapeutic agents, AraC and DNR (Fig. 7d) except for K562, which were highly resistant to these agents (data not shown). Parental cells and T315I-acquired sublines of TCCS and KOPM28 were equally sensitive to AraC and DNR, indicating that the T315I mutation of BCR-ABL1 specifically induced resistance to TKI but not to chemotherapeutic agents.

**Discussion** In the present study, we tried to introduce the T315I mutation of BCR-ABL1 into Ph+ leukemia cell lines by HR-mediated gene editing with the CRISPR/Cas9 system. Since BCR-ABL1 has been reported to repress a variety of genes involved in the HR pathway34–38, we analyzed their sensitivities to olaparib (a PARP1 inhibitor) to functionally evaluate the status of the HR pathway. We found that all four Ph+ myeloid leukemia cell lines were highly resistant, suggesting that their HR pathway is functionally not impaired. Indeed, we successfully established imatinib-resistant sublines of three Ph+ myeloid cell lines — K562, TCCS, and KOPM28 — which acquired the T315I mutation as a result of HR-mediated gene editing. We previously tried to introduce specific gene mutations of our interested genes in four Ph− ALL cell lines with the same strategy, but we failed to obtain sublines with the desired mutation. Of note, in the present study, all of the four cell lines that we used in the previous attempts turned out to be sensitive to PARP-1 inhibitor, suggesting that their HR pathway was functionally impaired. Thus, although further verifications are required, sensitivity of cancer cell lines to PARP1 inhibitor may be a useful biomarker to predict efficiency of HR-mediated gene editing with the CRISPR/Cas9 system.

To select successfully integrated cells, we used imatinib. In the previous reports15–17, imatinib-resistant sublines with T315I were established from Ph+ leukemia cell lines after 5–10 months’ culturing in the presence of increasing concentrations of imatinib. Long-term culture in the presence of increasing concentrations of imatinib also induced enhancement of BCR-ABL1 expression18 and/or upregulation of cell surface expression of P-gp19 as mechanisms for imatinib-resistance, suggesting that T315I-positive sublines of Ph+ leukemia cell lines may acquire additional mechanism(s) for imatinib-resistance during imatinib selection. Considering these previous reports, to allow an expansion of T315I integrated cells and prevent a spontaneous emergence of imatinib-resistant sublines, we initially cultured cells for 7 days in the absence of imatinib after electroporation. Furthermore, we used 1 μM of imatinib for selection to eliminate emergence of clones that are moderately resistant to imatinib due to mechanism(s) other than an acquisition of T315I mutation. As a result, we successfully expanded T315I acquired sublines of three myeloid Ph+ leukemia cell lines after short-term (7 to 26 days) imatinib selection. Enhancement of BCR-ABL1 expression and upregulation of cell surface expression of P-gp were not induced in imatinib-resistant sublines of three cell lines.

We prepared forward and reverse sgRNAs in combination with sense and anti-sense ssODNs. Efficiency of HR-mediated gene editing is reported to be affected by structure and composition of sgRNA and ssODN such as incorporation of silent mutation to block re-cutting of repaired loci19, distance between mutation site and cleavage site39, length of homology arms40,41, and strand complementarity or orientation of ssODN40–42. In the present study, all four combinations produced identical distance between mutation site and cleavage site and introduced
three silent mutations to block re-cutting of repaired loci. The highest efficiency was observed in the combination of reverse sgRNA and anti-sense ssODN, which was complementary to the transcribed strand and contained the NGG PAM sequence. This was inconsistent with previous reports using different delivery and modality of CRISPR/Cas9 system, since higher efficiency was reported to be obtained by ssODN that was complementary to the non-transcribed strand and by ssODN that was complementary to the PAM strand. Thus, delivery and modality of CRISPR/Cas9 system might affect an optimal combination of sgRNA and ssODN.

TCCS and KOPM28 have the BCR-ABL1 allele but not the ABL1 allele. We confirmed that all of the imatinib-resistant sublines of two cell lines had both native and recombination alleles of BCR-ABL1, suggesting that these two cell lines may serve as good models of acquired T315I mutation in BCR-ABL1. In contrast to TCCS and KOPM28, K562 has both BCR-ABL1 and ABL1 alleles, and its ABL1 allele also acquired the T315I mutation. Although it is unlikely that the induced ABL1 T315I mutation contributes to imatinib resistance, this may be a confounding issue limiting the use of the K562 subclones for drug testing. Removal of the ABL1 allele by a CRISPR/Cas9-induced deletion in K562 may resolve this problem.

T315I sublines from the three cell lines showed a marked resistance to dasatinib and nilotinib, as well as imatinib in comparison with their parental cells. Although ponatinib was developed as a potent TKI that can
inhibit all critical kinase domain mutations including T315I, its activity against the T315I mutant was reported to be modestly decreased in comparison with the activity against native ABL1 and BCR-ABL1 as follows. The IC\textsubscript{50} value of ponatinib in the kinase assay \textit{in vitro} was reported to be 0.37 and 2 nM for native ABL1 and T315I mutant, respectively. In Baf3 transfectants, the IC\textsubscript{50} value of ponatinib was reported to be 0.5 and 11 nM for native BCR-ABL1 and T315I mutant, respectively. In the present study, T315I sublines of TCCS and KOPM28 were sensitive to ponatinib, and their IC\textsubscript{50} values (approximately 0.2 and 20 nM, respectively) were significantly higher than those in parental cells (less than 0.1 nM). In K562, the sensitivities of parental cells and T315I sublines were identical. These observations demonstrated that parental cells and T315I sublines of three cell lines are useful models for the analysis of TKI sensitivities.

Brabetz \textit{et al.} recently introduced an oncogenic mutation (R140Q) of the \textit{IDH2} gene into K562 cells successfully using the CRISPR/Cas9 system. Since R140Q is located in exon 4 of the \textit{IDH2} gene, they inserted exons 4–11 with R140Q as a partial cDNA into exon 4 of the \textit{IDH2} gene locus via HR. In Ba3 transfectants, the IC\textsubscript{50} value of ponatinib was reported to be 0.5 and 11 nM for native BCR-ABL1 and T315I mutant, respectively. In the present study, T315I sublines of TCCS and KOPM28 were sensitive to ponatinib, and their IC\textsubscript{50} values (approximately 0.2 and 20 nM, respectively) were significantly higher than those in parental cells (less than 0.1 nM). In K562, the sensitivities of parental cells and T315I sublines were identical. These observations demonstrated that parental cells and T315I sublines of three cell lines are useful models for the analysis of TKI sensitivities.

\textbf{Figure 7.} TKIs and chemotherapeutic agents sensitivities in parental cells and T315I-acquired sublines of three cell lines. (a,b,c) Dose-response curves of nilotinib (a), dasatinib (b), and ponatinib (c) sensitivities in parental cells (blue line) and T315I-acquired sublines (#1 and #2) (red and green lines, respectively) of K562 (upper left), TCCS (upper right), and KOPM28 (lower left). The vertical axis indicates % viability in the alamarBlue cell viability assay and the horizontal axis indicates log concentrations of nilotinib (a), dasatinib (b), and ponatinib (c) (nM). (d) Dose-response curves of AraC (upper) and DNR (lower panel) sensitivities in parental cells (blue line) and T315I-acquired sublines (#1 and #2) (red and green lines, respectively) of TCCS (left) and KOPM28 (right panel). The vertical axis indicates % viability in the alamarBlue cell viability assay and the horizontal axis indicates log concentrations of AraC and DNR.
Methods

Cell lines. Twenty Ph-positive (Ph+) leukemia cell lines (16 lymphoid and four myeloid) listed in Table 1 were analyzed. K562, TCCS, KOPM28, and KOPM30 were Ph+ myeloid cell lines. KOPN30bi, KOPN56, KOPN57bi, KOPN66bi, KOPN72bi, KOPN83bi, YAMN73, YAMN91, Kasumi8, Nalm1, Nalm27, KCB1, TCCY, SU-PH2, and SK9 were Ph+ B-cell precursor leukemia cell lines. K562, TCCS, KOPM28, KOPN55bi, and Nalm1 were established from CML-BC with the p210 BCR-ABL1. KOPM30 and KOPN30bi were established from the same patient with Ph+ acute leukemia with the p190 BCR-ABL1 at different stages of the disease. KOPN56, TCCY, and Nalm27 were established from Ph+ acute lymphoblastic leukemia (ALL) with the p210 BCR-ABL1. YAMN73 was established from Ph+ ALL with the p203 BCR-ABL1 rearranged in major BCR. KOPN57bi, KOPN66bi, KOPN72bi, KOPN83bi, YAMN91, Kasumi8, KCB1, SU-PH2, and SK9 were established from Ph+ ALL with the p190 BCR-ABL1. Seventy-seven Ph- BCP-ALL cell lines listed in Supplemental Table 1 were used as control. All cell lines were maintained in RPMI1640 medium supplemented with 10% fetal calf serum (FCS).

alamarBlue cell viability assay. To determine the sensitivities to olaparib, imatinib, dasatinib, nilotinib, ponatinib, cytosine arabinoside (AraC), and daunorubicin (DNR), an alamarBlue cell viability assay (Bio-Rad Laboratories, Hercules, CA, USA) was performed. A total of 1–5 × 10⁵ cells were plated into a 96-well flat-bottom plate in triplicate and cultured for 68 hours in the presence or absence of seven concentrations of each drug. After a 6 hour additional incubation with alamarBlue, absorbance at 570 nm were monitored by a microplate spectrophotometer using 600 nm as a reference wavelength. Cell survival was calculated by expressing the ratio of the optical density of treated wells to that of untreated wells as a percentage. The concentration of drug required to reduce the viability of treated cells to 50% of untreated cells was calculated. The median of three independent assays was determined as 50% inhibitory concentration (IC₅₀) for each cell line.

Introduction of the T315I mutation by the CRISPR/Cas9 system. Two CRISPR guide sequences were designed using the CRISPR design tool (CRISPR DESIGN, http://crispr.mit.edu) as follow; 5′-tacctgattgcatgcagcagc-3′ (forward sgRNA) and 5′-aactcagtgatgatatagaacgg-3′ (reverse sgRNA). 102 base pair template ssODN in a transcribed strand (sense) direction and its complementary template ssODN in a non-transcribed strand (anti-sense) direction were synthesized by Integrated DNA technologies (Corvalle, IA, USA). The sequence of ssODN in the sense direction was as follows; 5′-gggtctcagccggagcccccctgcttcatatacatTaTGCaatattccagctacgtgacagattggtgctggag-3′. Four mutated nucleotides are capitalized. As a negative control, we used carrier ssODN (Integrated DNA technologies). Recombinant Cas9 nuclease with guide RNA (Integrated DNA technologies) was electroporated into cell lines as a ribonucleoprotein (RNP) complex with template ssODN following manufacturer’s protocol[40]. Briefly, RNP complex and template ssODN were electroporated into 1 × 10⁵ cells, which were untreated or pretreated with 10nM of SCR7[33,34] (Cayman Chemical, Ann Arbor, MI, USA) for 24 hours before electroporation, using Neon electroporation transfection system (Thermo Fisher Scientific). The electroporated cells were cultured in the absence or presence of 10nM of SCR7 for 24 hours in one well of 96 well plate. Forty-eight hours after electroporation, the electroporated cells were mixed with untreated cells and plated into 10–12 wells of 24-well plate. After 5 days selection in the absence of imatinib, the cells were cultured in the presence of 1µM of imatinib. During imatinib selection, half of the culture medium in each well was exchanged every 2–3 day with fresh medium containing 1µM of imatinib. When the imatinib-resistant cells were selectively expanded, imatinib-resistant sublines in each well were transferred to culture flask and expanded in the absence of imatinib for further experiments.

PCR analyses. To confirm HR in the BCR-ABL1 fusion gene, genomic DNA samples extracted from parental and imatinib-resistant sublines were amplified by PCR using forward (5′-ccacagcacagctctcag-3′) and reverse (5′-ctaggctgggttttga-3′) primers that were specific for introns 5 and 6 of the ABL1 gene, respectively. Each PCR product digested with EcoRI was electroporated. Direct sequencing of each PCR product was performed using the forward primer. To detect ABL1 transcripts, cDNA prepared from parental and imatinib-resistant sublines was amplified by RT-PCR using forward primers in exons 1a (5′-gtggctgctaatgattgag-3′) or 1b (5′-aggaatctggccggctaagc-3′) and reverse primer in exon 2 (5′-ggggctcaggagcactagc-3′). As a control, RT-PCR was also performed using forward primers in exons 6 (5′-ctctgctactgcgaatcctac-3′) and reverse primer in exon 7 (5′-ctctgcagctcagttc-3′). To distinctively sequence the ABL1 and the BCR-ABL1 transcripts, RT-PCR was performed using forward primers in exon 1b of the ABL1 gene (5′-aggtcgcggagctttcaggg-3′) or exon 13 of the BCR gene (5′-agattcctgtctgcaggtga-3′) and reverse primer in exon 6 of the ABL1 gene (5′-ctctctctctcagctctg-3′), respectively, and direct sequencing of the RT-PCR products was performed using the reverse primer.

Flow cytometric analyses. To evaluate cell surface expression of P-glycoprotein, cells were stained with a fluorescein isothiocyanate (FITC)-conjugated anti-P-glycoprotein antibody (Nichirei, Tokyo, Japan) and analyzed by flow cytometry (MACSQuant, BD Biosciences, San Jose, CA). To analyze phosphorylation status of CRKL, cell cycle, and apoptotic cell death, cells were cultured in the presence or absence of 1µM of imatinib for 24 hours except for detection of apoptosis in K562 cells (60 hours incubation). To evaluate phosphorylation status of CRKL, the cells were fixed with 10% formaldehyde at 37°C for 10 min and permeabilized with 90% methanol on ice for 30 min. After washing the cells twice with PBS/0.5% BSA, the cells were stained with anti-phospho CRKL (pTyr207) (#3811, Cell Signaling Technology, Danvers, MA, USA) and subsequently with Alexa Fluor 488-conjugated goat anti-rabbit IgG (H + L) (#A11008, Invitrogen, Carlsbad, CA, USA) and analyzed by flow cytometry. For cell cycle analysis, the cells fixed with 70% ethanol were stained with propidium iodide (PI) (Sigma, St. Louis, MO) and analyzed by flow cytometry. To detect apoptosis, the cells were stained with FITC-conjugated Annexin-V and 7AAD (MBL, Nagoya, Japan) and analyzed by flow cytometry.
Western blot analyses. Cells were solubilized in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 0.05% NaN₃, 1 mM phenylmethylsulfonyl fluoride, 100 μM sodium vanadate). The lysates were separated on a SDS-polyacrylamide gel under reducing conditions and then transferred to a nitrocellulose membrane. The membrane was incubated with anti-ABL1 antibody (#554148, BD Biosciences, Franklin Lakes, NJ, USA) and anti-alpha-Tubulin antibody (T1568, Sigma) at 4°C overnight, and then with horseradish peroxidase-labeled second antibody (MBL, Nagoya, Japan) at room temperature for 1 hour. The bands were developed using an enhanced chemiluminescence detection (ECL) kit (GE Healthcare, Little Chalfont, UK).

Statistics. Mann-Whitney test was applied for comparison of drug sensitivities, a paired t-test was for comparison in the same subject, and Kaplan-Meier analysis for comparison of efficiencies in the establishment of imatinib-resistant sublines.

Data availability. The authors declare that the data supporting the findings of this study are available within the paper and its supplementary information files.

References
1. Rosti, G., Castagnetti, F., Gugliotta, G. & Baccarani, M. Tyrosine kinase inhibitors in chronic myeloid leukemia: which, when, for whom? Nature reviews clinical oncology 14, 141–154 (2017).
2. Druker, B. I. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England journal of medicine 344, 1031–1037 (2001).
3. Druker, B. I. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature medicine 2, 561–566 (1996).
4. Thomas, D. A. et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with hyper-CVAD and imatinib mesylate. Blood 103, 4396–4407 (2004).
5. Towsiati, M. et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104, 3507–3512 (2004).
6. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001).
7. Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472–3475 (2002).
8. Azam, M., Latek, R. R. & Daley, G. Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831–843 (2003).
9. O ’Hare, T. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer research 65, 4500–4505 (2005).
10. O’Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and enhances mutation-based resistance. Cancer cell 16, 401–412 (2009).
11. Corbin, A. S., La Rosse, P., Stoffregen, E. P., Druker, B. I. & Deininger, M. W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101, 4611–4614 (2003).
12. von Bubnoff, N. et al. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer research 63, 6395–6404 (2003).
13. Tipping, A. J. et al. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia 18, 1352–1356 (2004).
14. Ricci, C. et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer research 62, 5995–5998 (2002).
15. Scappini et al. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing b210 Bcr/Abl protein. Cancer 100, 1459–1471 (2004).
16. Hirase, C., Maeda, Y., Taki, S. & Kanamaru, A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor. The Journal of biological chemistry 285, 5085–5096 (2010).
17. Mahon, F. X. et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96, 1070–1079 (2000).
18. Mahon, F. X. et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368–2373 (2003).
19. Couml, L. et al. Maltose genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
20. Mai, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
21. Sander, J. D. & Joung, J. K. CRISPR-Cas9 systems for editing, regulating and targeting genomes. Nature biotechnology 32, 347–355 (2014).
22. Nickoloff J. A., Jones D., Lee S. H., Williamson E. A., Hromas R. Drugging the Cancers Addicted to DNA Repair. Science 339, 819–823 (2013).
23. Bryant, H. E. et al. Specific killing of BCR-ABL-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
24. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
25. Pong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England journal of medicine 361, 123–134 (2009).
26. Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152–1158 (2017).
27. Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nature biotechnology 33, 538–542 (2015).
34. Chu, V. T. et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9 induced precise gene editing in mammalian cells. *Nature biotechnology* 33, 543–548 (2015).

35. Heisterkamp, N. & Groffen, J. Philadelphia-positive leukemia: a personal perspective. *Oncogene* 21, 8536–8540 (2002).

36. ten Hoeve, J. et al. Cellular interactions of CRKL, and SH2-H3 adaptor protein. *Cancer research* 54, 2563–2567 (1994).

37. Oda, T. et al. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. *The Journal of biological chemistry* 269, 22925–22928 (1994).

38. Price, K. E., Saleem, N., Lee, G. & Steinberg, M. Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. *OncoTargets and therapy* 6, 1111–1118 (2013).

39. Paquet, D. et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. *Nature* 533, 125–129 (2016).

40. Lin, S., Staahl, B. T., Alla, R. K. & Doudna, J. A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. *Elife* 3, e04766 (2014).

41. Liang, X., Potter, J., Kumar, S., Ravinder, N. & Chesnut, J. D. Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA. *J Biotechnol* 241, 136–146 (2017).

42. Baillie, P., Rivera-Torres, N., Strouse, B. & Kmiec, E. B. Regulation of gene editing activity directed by single-stranded oligonucleotides and CRISPR/Cas9 systems. *PLoS One* 10, e0129308 (2015).

43. Brabetz, O. et al. RNA-Guided CRISPR, Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations. *Molecular therapy nucleic acids* 6, 243–248 (2017).

44. Shall, O. How introns enhance gene expression. *The international journal of biochemistry & cell biology* (2017).

45. Sandberg, R., Neilson, J. R., Sarma, A., Sharp, P. A. & Burge, C. B. Proliferating cells express mRNAs with shortened 3′ untranslated regions and fewer microRNA target sites. *Science* 320, 1643–1647 (2008).

46. Mayer, C. & Bartel, D. P. Widespread shortening of 3′ untranslated regions by alternative cleavage and polyadenylation activates oncogenes in cancer cells. *Cell* 138, 673–684 (2009).

47. Bueno, M. J. et al. Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression. *Cancer cell* 29, 607–608 (2016).

48. Herschkovitz-Rokah, O. et al. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. *Cancer letters* 360, 245–256 (2015).

49. Herschkovitz-Rokah, O. et al. MiR 30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. *Cancer letters* 356, 597–605 (2015).

50. Jacobii, A. M. et al. Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes. *Methods* 121-122, 16–28 (2017).

Acknowledgements
The authors thank to Dr. N. Komatsu (TCCS; Juntendo University), Dr. T. Inaba (Kasumi8; Hiroshima University), Dr. Y. Sato (TCCY; The Japanese Red Cross College of Nursing), Dr. Y. Maeda (SU-Ph2; Kinki University), Dr. O. Komatsu (TCCS; Juntendo University), Dr. T. Inaba (Kasumi8; Hiroshima University), Dr. S. Okabe (SK9; Tokyo Medical University), and Dr. Y. Goto (KCB1; Kanagawa Children’s Medical Center) for providing Ph+ leukemia cell lines. This work was supported by JSPS KAKENHI Grant Number 15K09645 and AMED under Grant Number JP17ck0106253h0001.

Author Contributions
T.I., K.S. and S.N. conceptualized and designed experiments. M.T., T.I. and K.K. performed cell culture. M.T. and K.K. performed immunoblotting and flow cytometric analyses. M.T., K.S., M.A. and A.W. performed PCR analyses. T.I., M.A., D.H., T.S., H.O., K.A. and K.G. performed drug sensitivity assays. M.T., T.I., M.A. and K.K. analyzed data. M.T. and T.I. co-wrote the paper. S.K. supervised the study. All authors edited the paper.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-27767-6.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018